AverTox® (galantamine) has been demonstrated in animal models to be effective in improving survival when administered following a lethal nerve agent exposure in conjunction with existing conventional care drugs. To further the development of this application of the drug, the NIH NINDS CounterACT program has approved support for Countervail’s pre-proposal for a Non-GLP Single Dose Range-Finding Toxicity Study.